Melbourne, Australia, 22 June 2016: Neuren Pharmaceuticals (ASX: NEU) today announced that IP Australia has issued a Notice of Grant for a new patent that covers the use of trofinetide for the treatment of Autism Spectrum Disorders, including Rett syndrome, Fragile X syndrome, Asperger syndrome and autism. Patent number AU2012209466 expires in January 2032.
Ann: Grant of new patent for Autism Spectrum Disorders-NEU.AX, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.10 |
Change
-0.800(5.76%) |
Mkt cap ! $1.629B | |||
| Open | High | Low | Value | Volume |
| $13.95 | $13.96 | $12.88 | $9.534M | 725.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 266 | $13.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.15 | 1619 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |